glp-1 agonist drugs oral Market Overview: Agonists and the Obesity Market | Blog Oral GLP‑1 Therapy Type 2

Both produce real results

One of the reasons GLP-1 receptor agonists have gained so much attention is their ability to help with weight loss

The BALANCE model, which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, represented a structured attempt to provide GLP-1 access through government programs while controlling costs through direct manufacturer negotiation

Average Weight Loss in the Orforglipron phase 3 ATTAIN-1 Trial Across the 72-week study period, participants: Lost up to 15% of their body weight at the highest dose At 36 mg: 54.6% lost 10%, 36.0% lost 15%, 18.4% lost 20% body weight (all higher than placebo)